Home / Health / New Hot Flash Drug Approved: What You Need to Know
New Hot Flash Drug Approved: What You Need to Know
18 Nov
Summary
- FDA approved elinzanetant (Lynkuet) in October for hot flashes.
- The drug is a non-hormonal option for menopausal symptom relief.
- Hot flashes are linked to health risks like osteoporosis and cardiovascular disease.
A new non-hormonal medication, elinzanetant (Lynkuet), has received FDA approval for treating hot flashes and night sweats. This development offers a significant option for women experiencing bothersome menopausal symptoms, particularly those unable to use hormone therapy. The drug has demonstrated efficacy in clinical trials, working across different types of menopause and even in women with breast cancer.
Elinzanetant targets specific brain receptors to regulate temperature fluctuations caused by declining estrogen levels during menopause. While hormone therapy remains the most effective treatment for many, this new option provides a valuable alternative. Potential side effects may include sleepiness, fatigue, and headaches, and it is recommended to take the capsule at bedtime.
Beyond symptom relief, it's crucial to understand that persistent hot flashes are linked to increased health risks, including osteoporosis and cardiovascular disease. While elinzanetant addresses the symptoms, it does not treat bone loss. Consulting a healthcare professional remains essential for personalized treatment advice and to manage menopausal symptoms and associated health concerns effectively.
